Can Biliary Carcinoembryonic Antigen Identify Colorectal Cancer Patients with Occult Hepatic Metastases?
Tóm tắt
Twenty-five percent of radically treated colorectal cancer patients already have occult hepatic metastases (OHM) that will later be observed during postoperative follow-up. Instrumental examinations, i.e., intraoperative ultrasound or Doppler perfusion index, have not improved diagnosis. As carcinoembyonic antigen (CEA) levels are useful to reveal hepatic metastases from colorectal cancer, determination of CEA in the bile rather than the blood may allow preclinical diagnosis of OHM thanks to the reduced volume of bile. One hundred radically treated colorectal cancer patients were enrolled in the study. Bile was withdrawn from the gallbladder intraoperatively and biliary CEA levels determined using an immuno-enzymatic method (normal value 0–5 ng/ml). Eighty-nine fully evaluable patients were followed up for three years postoperatively to monitor hepatic metastases. Preoperative blood CEA, lymph node metastases and biliary CEA were compared in order to assess which procedure was more efficient in identifying patients who would develop hepatic metastases. Eleven of the 89 evaluable patients developed hepatic metastases: 9/11 presented elevated biliary CEA levels (mean: 12.73; range: 5.1–26.2); 8/11 had high preoperative blood CEA values; and 9/11 were at anatomopathological stage N+. In the 78 patients who did not develop hepatic metastases, biliary CEA was within normal limits in 73/78, preoperative blood CEA was normal in 60/78, and 58/78 patients were at anatomopathological stage N−. Hence, the sensitivity of biliary CEA was 81.8%, specificity was 93.6%, and diagnostic accuracy was 92.1%. Determination of biliary CEA seems to be more efficient in identifying patients presenting OHM who require frequent clinical examinations or adjuvant cancer treatment.
Tài liệu tham khảo
Li Destri G, Craxi G, Rinzivillo C, et al. Il follow-up colorettale. Nostra esperienza. Chirurgia 1996;9:261–267
Finlay IG, McArdle CS. Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986;73:732–735
Adson MA. Resection of liver metastases: when is it worthwhile? World J Surg 1987;11:511–520
Fantini GA, De Cosse JJ. Surveillance strategies after resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1990;171:267–273
Finlay IG, Meek D, Brunton F, et al. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75:641–644
Patel NA, Roh MS. Utility of intraoperative liver ultrasound. Surg Clin North Am 2004;84:513–524
Takeuchi N, Ramirez JN, Mortensen NJ, et al. Intraoperative ultrasonography in the diagnosis of hepatic metastases during surgery for colorectal cancer. Int J Colorectal Dis 1996;11:92–95
Leen E, Angerson WJ, Wotherspoon H, et al. Comparison of the Doppler perfusion index and intraoperative ultrasonography in diagnosing colorectal liver metastases. Evaluation with postoperative follow-up results. Ann Surg 1994;220:663–667
Stone MD, Kane R, Bothe A, et al. Intraoperative ultrasound imaging of the liver at the time of colorectal cancer resection. Arch Surg 1994;129:431–435
Kopljar M, Brkljacic B, Doko M, et al. Nature of Doppler perfusion index changes in patients with colorectal cancer liver metastases. J Ultrasound Med 2004;23:1295–300
Glover C, Douse P, Kane P, et al. Accuracy of investigations for asymptomatic colorectal liver metastases. Dis Colon Rectum 2002;45:476–484
Kruger S, Strobel D, Wehler M, et al. [Hepatic Doppler perfusion index—a sensitive screening method for detecting liver metastases?] Ultraschall Med 2000;21:206–209
Fong Y. Doppler perfusion index in colorectal cancer. Lancet 2000;355:5–6
Li Destri G, Greco S, Rinzivillo C, et al. Monitoring carcinoembryonic antigen in colorectal cancer: is it still useful? Surg Today 1998;28:1233–1236
Li Destri G, Rinzivillo C, Craxi G, et al. Colorectal follow-up planning modified on the basis of our personal experience. Dig Surg 1998;15:64–68
Sugarbaker PH, Pianola FJ, Dwyer A, et al. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79–87
Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219:174–182
Yeatman TJ, Rimura AK, Copeland EM, et al. Rapid analysis of carcinoembryonic antigen levels in gallbladder bile. Ann Surg 1991;213:113–117
Li Destri G, Curreri R, Lanteri R, et al. Biliary carcinoembryonic antigen in the diagnosis of occult hepatic metastases from colorectal cancer. J Surg Oncol 2002;81:8–11
Paul AA, Visser JJ, van Kamp GJ, et al. A simple extraction procedure for the determination of carcinoembryionic antigen in gallbladder bile. Ann Clin Biochem 1995;32:332–333
Paul MA, Visser JJ, Mulder C, et al. Detection of occult liver metastases by measurement of biliary carcinoembryonic antigen concentrations. Eur J Surg 1996;162:483–488
Waisberg J, Palma RT, Neto LC, et al. Biliary carcinoembryonic antigen lavels in diagnosis of occult hepatic metastases from colorectal carcinoma. World J Gastroenterol 2003;9:1589–1593
Gennari L. Le metastasi epatiche. Chirurgia 1995;8:175–176
Taylor I. Liver metastases from colorectal cancer. Lessons from past and present clinical studies. Br J Surg 1996;83:456–460
Wiratkapun S, Kraemer M, Seow-Choen F, et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2001;44:231–235
Wang WS, Lin JK, Chiou TJ, et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000;30:12–16
Allende T, Garcia Muniz JL, Vizoso F, et al. Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer. Rev Esp Med Nucl 2001;20:358–364
Ishizuka D, ShiraiY, Sakai Y, et al. Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19–9 levels. Int J Colorectal Dis 2001;16:32–37
Marquena J, Acosta MA, Garcia-Anguiano F, et al. Use of the preoperative levels of CEA in patients with colorectal cancer. Hepatogastroenterology 2003;50:1017–1020
Braat AE, Oosterhuis JWA, Moll FCP, et al. Successful sentinel node identification in colon carcinoma using Patent Blue V. Eur J Surg Oncol 2004;30:633–637
Yuan HY, Cheng FL, Wei ZZ, et al. Clinical significance of detecting lymph node micrometastasis of colorectal cancer by reverse transcriptase-polymerase chain reaction (RT-PCR)] Ai Zheng. 2004;23:1069–1073
Mukai M, Sato S, Komatsu M, et al. Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes’ B colorectal cancer. Oncol Rep 2003;10:1177–1181
Li Destri G, Gravagna G, Zappalà O, et al. Linfoadenectomia “en bloc” per cancro colorettale: numero di linfonodi e ratio come fattori prognostici. Tumori 2005;4(suppl):18–20
Paganuzzi M, Onetto M, De Paoli M, et al. Carcinoembryonic antigen (CEA) in serum and bile of colorectal cancer patients with or without detectable liver metastases. Anticancer Res 1994;14:1409–1412
Kutun S, Celik A, Hatoboglu C, et al. Carcinoembryonic antigen to detect hepatic metatases of colorectal cancers. Surg Today 2003;33:590–594
Dorrance HR, McGregor JR, McAllister RJ, et al. Bile carcinoembryonic antigen levels and occult hepatic metastases from colorectal cancer. Dis Colon Rectum 2000;43:1292–1295
Frikart L, Fournier K, Mach JP, et al. Potential value of biliary CEA assay in early detection of colorectal adenocarcinoma liver metatases. Eur J Surg Oncol 1995;21:276–279
Ishida H, Yoshinaga K, Gonda T, et al. Biliary carcinoembrionic antigen levels can predict metachronous liver metastasis of colorectal cancer. Anticancer Res 2000;20:523–526
Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997;89:497–505
Beart RW, Moertel CG, Wieand HS, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990;125:897–901
Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466–1475
Nitti D, Wils J, Sahmoud T, et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organisation for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 1997;33:1209–1215
Rougier P, Sahmoud T, Nitti D, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998;351:1677–1681
Focan C, Bury J, Beauduin M, et al. Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Regional d’Etude du Cancer Colo-Rectal (Belgium). Anticancer Drugs 2000;11:549–554
Fielding LP, Hittinger R, Grace RH, et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502–506
Metzger U, Laffer U, Egeli R, et al. Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research. Chirurg 1994;65:509–513
Yamamura T, Yabe K, Oka H, et al. Intraportal Chemotherapy for Colorectal Cancer Group. [Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group.] Gan To Kagaku Ryoho 2002;29:1765–1771